Auranofin
- Generic Name
- Auranofin
- Brand Names
- Ridaura
- Drug Type
- Small Molecule
- Chemical Formula
- C20H34AuO9PS
- CAS Number
- 34031-32-8
- Unique Ingredient Identifier
- 3H04W2810V
- Background
Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading...
- Indication
Used in the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis.
- Associated Conditions
- Rheumatoid Arthritis
- Associated Therapies
- -
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT03456700
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure
- Conditions
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 30
- Registration Number
- NCT02961829
- Locations
- 🇧🇷
CCDI, Sao Paulo, SP, Brazil
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 10
- Registration Number
- NCT02770378
- Locations
- 🇩🇪
University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany
Auranofin for Giardia Protozoa
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2023-01-26
- Target Recruit Count
- 93
- Registration Number
- NCT02736968
- Locations
- 🇧🇩
International Center for Diarrheal Disease Research Bangladesh - Parasitology, Dhaka, Bangladesh
🇧🇩Rajshahi Medical College Hospital, Rajshahi 6000, Bangladesh
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Vaccine and Gene Therapy Institute, Florida
- Registration Number
- NCT02176135
- Locations
- 🇺🇸
University of Miami - AIDS Clinical Research Unit, Miami, Florida, United States
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT02126527
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Auranofin PK Following Oral Dose Administration
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-04-28
- Target Recruit Count
- 15
- Registration Number
- NCT02089048
- Locations
- 🇺🇸
Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States
Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT02063698
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT01747798
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 29
- Registration Number
- NCT01737502
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.